Organogenesis Holdings Inc. (ORGO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001661181 0001661181 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Ju
How this was made
The 30-second read
Why it matters
The disclosure formalizes shareholder-approved governance items (director elections, advisory executive compensation approval, and ratification of the independent auditor) and confirms Garrett Lustig’s re-election via Series A preferred stockholder consent.
Market read
Primarily governance/newsflow; no new operating or financial catalyst is disclosed in the provided text.
What to watch
Traders may still want to check the referenced April 30, 2026 definitive proxy statement for any compensation changes, director qualifications, or proposals that could signal longer-term strategy—those details are not included in the scraped 8-K text.
Background
This SEC 8-K reports Item 5.02 (director re-election/compensatory arrangements via proxy incorporation) and Item 5.07 (annual meeting voting results) for Organogenesis Holdings Inc.
Ticker impact
ORGO filed an 8-K confirming Series A preferred holders re-elected director Garrett Lustig and reports annual meeting director/compensation/accounting-firm vote results.
Low likelihood of a sustained price move; any reaction is likely limited to governance/newsflow rather than operating performance.
The filing contains voting outcomes and incorporation by reference to the proxy statement, with no new financial guidance, deal, litigation, or operational catalyst disclosed in the text provided.
Market effects
No sector-level implications; this is company-specific governance disclosure.
None indicated.
None indicated.
Counterpoint
Even without operating news, governance votes can matter if investors were concerned about board composition or executive compensation alignment; however, the filing provides no controversy or change details beyond re-election.
Key entities
- companyOrganogenesis Holdings Inc.
Nasdaq-listed issuer filing the 8-K with annual meeting and director/compensation/auditor vote results.
- personGarrett Lustig
Re-elected to ORGO’s board of directors for the next annual meeting term.
- entityRSM US LLP
Ratified by shareholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
